Vir Biotechnology, Inc.: financial statements

VIRNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$9.15

November 18, 2026Market cap $1.6B

What Ploutos Investor adds for Vir Biotechnology

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 9 fiscal years, from 2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 22% since Nov 4, 2026, when the 10-Q these figures come from was filed ($11.77 then, $9.15 on Nov 18, 2026). The figures date from before that move.10-Q

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

-10.8% a year over 2 years

Line202320242025Average a year
Revenue $86M$74M$69M-10.8%
Cost of revenue $2.8M$845.0K$26.0K-90.3%
Gross profit $83M$73M$69M-9.4%
Operating income -$684M-$587M-$479M
Net income -$615M-$522M-$438M
Earnings per share -$4.59-$3.83-$3.16
Earnings per share, basic -$4.59-$3.83-$3.16
Margins
Gross margin 96.8%98.9%100.0%
Operating margin -794.0%-791.3%-699.2%
Net margin -713.7%-703.4%-638.9%

Financial statements

VIR's revenue, profits and cash flows from 2017 to 2022, 6 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: License And Collaboration Revenue –, Other Revenue $2.1M, Grant $47M, Profit Sharing Amount $1.5M, Profit Sharing Amount Previously Constrained Released $36M
  • 2024: License And Collaboration Revenue $61M, Other Revenue $2.3M, Grant $10M, Profit Sharing Amount $9.1M, Profit Sharing Amount Previously Constrained Released –
  • 2025: License And Collaboration Revenue $63M, Other Revenue $3.4M, Grant $2.0M, Profit Sharing Amount –, Profit Sharing Amount Previously Constrained Released –
Product202320242025Share 2025
License And Collaboration Revenue–$61M$63M92%
Other Revenue$2.1M$2.3M$3.4M4.9%
Grant$47M$10M$2.0M3.0%

By segment

VIR's revenue by product line from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 7 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$98M Leases-0.0% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$98M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Goodwill by segment

Dec 31, 2025

Total goodwill

$17M

The company does not state its goodwill by segment, at December 31, 2025. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

-0.0%

-21.0 pts

The company paid -0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

-17.4 pts

Difference the filing does not itemize

-3.6 pts

Effective rate

-0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Taxes: deferred and paid

The deferred part was 140.1% of the tax charge in the year to Dec 31, 2025.

  • The deferred share is higher than at nine in ten S&P 500 companies.
Deferred share, year to Dec 31, 2025$304.0K of $217.0K
140.1%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

Receivables and inventory against sales are not shown: a figure it needs is missing from the company's structured filings.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do Vir Biotechnology's filings show?

These are Vir Biotechnology's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about VIR's financials

Didn't find what you were looking for?

Ask us
How much revenue did VIR have in 2025?

Vir Biotechnology had revenue of $69M and net income of -$438M in fiscal 2025, a net margin of -638.9%.

How much debt does VIR have?

On December 31, 2025 Vir Biotechnology had total assets of $1.0B, debt of – and shareholders' equity of $765M.

How much free cash flow does VIR have?

In fiscal 2025 Vir Biotechnology had cash from operations of -$392M and spent $4.8M on capital expenditure, leaving -$397M of free cash flow.

Where are the figures from?

From Vir Biotechnology, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.